CN104602681A - 取代的吡啶酰胺激酶抑制剂 - Google Patents
取代的吡啶酰胺激酶抑制剂 Download PDFInfo
- Publication number
- CN104602681A CN104602681A CN201380042757.0A CN201380042757A CN104602681A CN 104602681 A CN104602681 A CN 104602681A CN 201380042757 A CN201380042757 A CN 201380042757A CN 104602681 A CN104602681 A CN 104602681A
- Authority
- CN
- China
- Prior art keywords
- amino
- base
- alkyl
- picolinamide
- halo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 CI1=CC=C*2C1=CC*2 Chemical compound CI1=CC=C*2C1=CC*2 0.000 description 14
- VWIZWOFQUCKFMP-NDWVUGOJSA-N C/C(/[IH]C)=C\C=N/C Chemical compound C/C(/[IH]C)=C\C=N/C VWIZWOFQUCKFMP-NDWVUGOJSA-N 0.000 description 1
- DMWONLCXLYDCII-KCYZJLMUSA-O CC(C)C(/C=C(/NC(C(C(N)=O)N=C1)C=C1N[C@H](CCCC1)[C@H]1N)\[OH2+])=N Chemical compound CC(C)C(/C=C(/NC(C(C(N)=O)N=C1)C=C1N[C@H](CCCC1)[C@H]1N)\[OH2+])=N DMWONLCXLYDCII-KCYZJLMUSA-O 0.000 description 1
- BDOONBNSDPCCIQ-UHFFFAOYSA-N CC(C)c1c[nH]c2c1nccc2 Chemical compound CC(C)c1c[nH]c2c1nccc2 BDOONBNSDPCCIQ-UHFFFAOYSA-N 0.000 description 1
- LSDYIOZRBGVBQN-UHFFFAOYSA-N CCCC(C)c1c(N)[nH]nc1 Chemical compound CCCC(C)c1c(N)[nH]nc1 LSDYIOZRBGVBQN-UHFFFAOYSA-N 0.000 description 1
- BOIZFJCUVXGXTH-UHFFFAOYSA-N CCCC(N(C)[ClH]C)O Chemical compound CCCC(N(C)[ClH]C)O BOIZFJCUVXGXTH-UHFFFAOYSA-N 0.000 description 1
- JGZQFUHQHQLXRT-UHFFFAOYSA-N C[F]c(cc1)cc2c1[nH]cc2 Chemical compound C[F]c(cc1)cc2c1[nH]cc2 JGZQFUHQHQLXRT-UHFFFAOYSA-N 0.000 description 1
- MEBSFGDAHQKSOE-UHFFFAOYSA-N C[IH]c1ncc[s]1 Chemical compound C[IH]c1ncc[s]1 MEBSFGDAHQKSOE-UHFFFAOYSA-N 0.000 description 1
- WGRRBPXKOSKCJO-UHFFFAOYSA-N Cc(cc1)nc2c1[nH]cc2 Chemical compound Cc(cc1)nc2c1[nH]cc2 WGRRBPXKOSKCJO-UHFFFAOYSA-N 0.000 description 1
- HMXZIJABHDJYQQ-UHFFFAOYSA-N Cc1c2[nH]ccc2ncc1 Chemical compound Cc1c2[nH]ccc2ncc1 HMXZIJABHDJYQQ-UHFFFAOYSA-N 0.000 description 1
- VUUJUMZCZFHRFZ-UHFFFAOYSA-N Cc1cc(cn[nH]2)c2nc1 Chemical compound Cc1cc(cn[nH]2)c2nc1 VUUJUMZCZFHRFZ-UHFFFAOYSA-N 0.000 description 1
- RLYUNPNLXMSXAX-UHFFFAOYSA-N Cc1cnc[s]1 Chemical compound Cc1cnc[s]1 RLYUNPNLXMSXAX-UHFFFAOYSA-N 0.000 description 1
- HNMRRDNEGHFDJD-UHFFFAOYSA-N Cc1n[s]c(Nc2c(C(N)=O)ncc(NC3(C(CS(C)(=O)=O)C3)C(N)=N)c2)c1 Chemical compound Cc1n[s]c(Nc2c(C(N)=O)ncc(NC3(C(CS(C)(=O)=O)C3)C(N)=N)c2)c1 HNMRRDNEGHFDJD-UHFFFAOYSA-N 0.000 description 1
- WOTIUKDGJBXFLG-UHFFFAOYSA-N Cc1n[s]cc1 Chemical compound Cc1n[s]cc1 WOTIUKDGJBXFLG-UHFFFAOYSA-N 0.000 description 1
- GUVUIZBOCKWUCM-UHFFFAOYSA-N IC1NC2C=CC=NC2C1 Chemical compound IC1NC2C=CC=NC2C1 GUVUIZBOCKWUCM-UHFFFAOYSA-N 0.000 description 1
- AXEMGZZPZPKOAG-UHFFFAOYSA-N I[IH]C1NOC=C1 Chemical compound I[IH]C1NOC=C1 AXEMGZZPZPKOAG-UHFFFAOYSA-N 0.000 description 1
- IENVYPZXMHMGLD-UHFFFAOYSA-N Ic1ccn[s]1 Chemical compound Ic1ccn[s]1 IENVYPZXMHMGLD-UHFFFAOYSA-N 0.000 description 1
- MALZFDMSYJAYFR-UHFFFAOYSA-M NC(Cc(ncc(N)c1)c1Nc1cc([N-]/N=C\C=N)ccc1)=O Chemical compound NC(Cc(ncc(N)c1)c1Nc1cc([N-]/N=C\C=N)ccc1)=O MALZFDMSYJAYFR-UHFFFAOYSA-M 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261663510P | 2012-06-22 | 2012-06-22 | |
| US61/663,510 | 2012-06-22 | ||
| US13/841,867 US20140113931A1 (en) | 2012-06-22 | 2013-03-15 | Substituted picolinamide kinase inhibitors |
| US13/841,867 | 2013-03-15 | ||
| PCT/US2013/045987 WO2013192046A2 (en) | 2012-06-22 | 2013-06-14 | Substituted picolinamide kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104602681A true CN104602681A (zh) | 2015-05-06 |
Family
ID=49769665
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201380042757.0A Pending CN104602681A (zh) | 2012-06-22 | 2013-06-14 | 取代的吡啶酰胺激酶抑制剂 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20140113931A1 (enExample) |
| EP (1) | EP2863905A4 (enExample) |
| JP (1) | JP2015523996A (enExample) |
| CN (1) | CN104602681A (enExample) |
| AU (1) | AU2013277473A1 (enExample) |
| CA (1) | CA2877469A1 (enExample) |
| HK (1) | HK1209316A1 (enExample) |
| IL (1) | IL235935A0 (enExample) |
| SG (1) | SG11201408074VA (enExample) |
| WO (1) | WO2013192046A2 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107709315A (zh) * | 2015-06-02 | 2018-02-16 | 药品循环有限责任公司 | 布鲁顿酪氨酸激酶的抑制剂 |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20160093675A (ko) | 2013-12-05 | 2016-08-08 | 파마싸이클릭스 엘엘씨 | 브루톤 티로신 키나제의 억제제 |
| EP3898614A1 (en) | 2018-12-17 | 2021-10-27 | Tolremo Therapeutics AG | Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment, amelioration or prevention of cancer |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1184376A1 (en) * | 1999-06-09 | 2002-03-06 | Yamanouchi Pharmaceutical Co. Ltd. | Novel heterocyclic carboxamide derivatives |
| WO2012061418A2 (en) * | 2010-11-01 | 2012-05-10 | Portola Pharmaceuticals, Inc. | Benzamides and nicotinamides as syk modulators |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20100132550A (ko) * | 2008-04-16 | 2010-12-17 | 포톨라 파마슈티컬스, 인코포레이티드 | ｓｙｋ 또는 ＪＡＫ 키나제 억제제로서의 ２,６－디아미노-피리미딘－５－일－카르복스아미드 |
| EP2443123B1 (en) * | 2009-06-15 | 2017-04-05 | Rigel Pharmaceuticals, Inc. | Small molecule inhibitors of spleen tyrosine kinase (syk) |
| JP2014503000A (ja) * | 2011-01-21 | 2014-02-06 | アッヴィ・インコーポレイテッド | キナーゼのピコリンアミド阻害剤 |
| US9216173B2 (en) * | 2011-10-05 | 2015-12-22 | Merck Sharp & Dohme Corp. | 2-Pyridyl carboxamide-containing spleen tyrosine kinase (SYK) inhibitors |
| WO2014153280A1 (en) * | 2013-03-22 | 2014-09-25 | Merck Sharp & Dohme Corp. | 2-pyridyl carboxamide-containing spleen tyrosine kinase (syk) inhibitors |
-
2013
- 2013-03-15 US US13/841,867 patent/US20140113931A1/en not_active Abandoned
- 2013-06-14 SG SG11201408074VA patent/SG11201408074VA/en unknown
- 2013-06-14 CA CA2877469A patent/CA2877469A1/en not_active Abandoned
- 2013-06-14 HK HK15109941.4A patent/HK1209316A1/xx unknown
- 2013-06-14 WO PCT/US2013/045987 patent/WO2013192046A2/en not_active Ceased
- 2013-06-14 AU AU2013277473A patent/AU2013277473A1/en not_active Abandoned
- 2013-06-14 JP JP2015518468A patent/JP2015523996A/ja active Pending
- 2013-06-14 CN CN201380042757.0A patent/CN104602681A/zh active Pending
- 2013-06-14 EP EP13807089.1A patent/EP2863905A4/en not_active Withdrawn
-
2014
- 2014-11-27 IL IL235935A patent/IL235935A0/en unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1184376A1 (en) * | 1999-06-09 | 2002-03-06 | Yamanouchi Pharmaceutical Co. Ltd. | Novel heterocyclic carboxamide derivatives |
| WO2012061418A2 (en) * | 2010-11-01 | 2012-05-10 | Portola Pharmaceuticals, Inc. | Benzamides and nicotinamides as syk modulators |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107709315A (zh) * | 2015-06-02 | 2018-02-16 | 药品循环有限责任公司 | 布鲁顿酪氨酸激酶的抑制剂 |
Also Published As
| Publication number | Publication date |
|---|---|
| US20140113931A1 (en) | 2014-04-24 |
| HK1209316A1 (en) | 2016-04-01 |
| SG11201408074VA (en) | 2015-01-29 |
| CA2877469A1 (en) | 2013-12-27 |
| EP2863905A2 (en) | 2015-04-29 |
| WO2013192046A3 (en) | 2014-02-27 |
| EP2863905A4 (en) | 2015-12-16 |
| IL235935A0 (en) | 2015-01-29 |
| AU2013277473A1 (en) | 2015-02-05 |
| WO2013192046A2 (en) | 2013-12-27 |
| JP2015523996A (ja) | 2015-08-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104470363A (zh) | 1,2,4-三嗪-6-甲酰胺激酶抑制剂 | |
| CN103282352B (zh) | 作为syk调节剂的苯甲酰胺类和烟酰胺类 | |
| CA2394809C (en) | Benzazole derivatives and their use as jnk modulators | |
| US9533986B2 (en) | Bicyclic dihydropyridone kinase inhibitors | |
| CN104066431B (zh) | 吡嗪激酶抑制剂 | |
| US9676756B2 (en) | Substituted pyrimidinyl kinase inhibitors | |
| JP2018524331A (ja) | ヘテロアリール置換のアミノピリジン化合物 | |
| BR112015004529B1 (pt) | Alcóxi pirazóis, seu uso como ativadores de guanilato ciclase solúvel e composição farmacêutica que os compreende | |
| US9469654B2 (en) | Bicyclic oxa-lactam kinase inhibitors | |
| CN104602681A (zh) | 取代的吡啶酰胺激酶抑制剂 | |
| CN107635996A (zh) | 咪唑并二氮*化合物 | |
| HK1209277B (en) | 1,2,4-triazine-6-carboxamide kinase inhibitors | |
| CN118515675A (zh) | 一种α5-GABAA受体调节剂及其用途 | |
| HK1213252B (en) | Bicyclic dihydropyridone kinase inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20150506 |
|
| WD01 | Invention patent application deemed withdrawn after publication |